HIV/AIDS Topics Bristol-Myers Squibb Announces Copayment Assistance Programs for Atazanavir (Reyataz), Efavirenz (Sustiva), and Atripla
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 April 2009 14:12
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) this month announced new copayment assistance programs for 3 of its antiretroviral medications. BMS will provide assistance with payments for atazanavir (Reyataz) and efavirenz (Sustiva), while BMS in partnership with Gilead Sciences will provide assistance for the Atripla (efavirenz/tenofovir/emtricitabine) fixed-dose combination pill.
Antiretroviral Treatment Interruption May Be a Viable Strategy if CD4 Cell Count Remains High
- Details
- Category: HIV Treatment
- Published on Friday, 24 April 2009 14:12
- Written by Liz Highleyman
Several studies over the past few years have contributed to a growing body of evidence indicating that interruption of antiretroviral therapy (ART) is a potentially risky strategy.
CROI 2009: Cancer Incidence in Clinical Trials of Raltegravir (Isentress)
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 24 March 2009 13:57
- Written by HIVandHepatitis.com
The first-in-class HIV integrase inhibitor, raltegravir (Isentress), was approved by the U.S. Food and Drug Administration in October 2007. During the drug's development, some clinical trials suggested that participants taking raltegravir had a higher rate of malignancies, though this was not confirmed in later studies.
Gilead Initiates Phase 2 Clinical Trial of Once-daily, Single-tablet, 4-drug Combination Pill Containing Integrase Inhibitor Elvitegravir
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 21 April 2009 14:12
- Written by Gilead Sciences
Gilead Sciences announced on April 17, 2009 that the company has initiated a Phase 2 clinical trial to assess the safety and efficacy of the new "QUAD" 4-drug combination pill containing elvitegravir, GS 9350, and emtricitabine/tenofovir (the drugs in the Truvada pill) versus the 3-drug efavirenz/tenofivir/emtricitabine (Atripla) combination pill in treatment-naive HIV positive adults.
HIV/AIDS Experts and Advocates Say Research Should Focus on a Cure
- Details
- Category: Search for a Cure
- Published on Friday, 20 March 2009 14:12
- Written by Liz Highleyman
Effective combination antiretroviral therapy has dramatically reduced rates of illness and death among people with HIV, but it does not cure the disease. Recent research presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) last month in Montreal showed that even though today's best antiretroviral drugs can completely suppress viral replication, HIV remains in the body in resting CD4 T-cells and probably also in another as-yet unidentified "reservoir."
U.S. Agencies Release Updated Opportunistic Infection and Pediatric Antiretroviral Therapy Guidelines
- Details
- Category: HIV Treatment Guidelines
- Published on Tuesday, 31 March 2009 14:12
- Written by Liz Highleyman
In recent weeks, U.S. agencies have released updated version of 2 sets of guidelines for treatment of people with HIV/AIDS.
Methadone Appears Not to Interact with HIV Protease Inhibitors
- Details
- Category: HIV Treatment
- Published on Friday, 20 March 2009 14:12
- Written by Liz Highleyman
HIV protease inhibitors (PIs) are processed by the cytochrome P450 (CYP450) system in the liver and can interfere with the activity of specific CYP450 enzymes. This can lead to slower processing -- and thus higher levels -- of other drugs metabolized by the same enzymes.
More Articles...
- Experimental NRTI Apricitabine Demonstrates Good Antiviral Activity with No Serious Side Effects at 96 Weeks
- FDA Approves Generic NRTI Combinations for PEPFAR Program
- CROI 2009: Treatment Intensification with Raltegravir (Isentress) Does Not Eradicate Residual HIV
- CROI 2009: Large Meta-analysis Indicates Antiretroviral Therapy Works as Well for Women as for Men
- CROI 2009: ESPRIT and SILCAAT Studies Find No Long-term Benefits of IL-2
Web Design and Development by